LyGenesis is developing cell therapies that use the body’s lymph nodes as sites for growing functional tissue. Built on research by University of Pittsburgh scientist and cofounder Eric Lagasse, the Pittsburgh company is pursuing organ regeneration for patients with serious disease. [1] [2]
Its investigational liver therapy delivers donated liver cells into upper abdominal lymph nodes using endoscopic ultrasound, with the goal of growing functional liver tissue. The Phase 2a program began dosing patients in April 2024 and received an independent monitoring board’s recommendation to continue and increase dosing in March 2025. [3] [4]
Alongside its liver program, LyGenesis is exploring earlier-stage applications involving the thymus, kidneys and pancreas. [5]